DEEPMIND SPINOFF'S AI-DESIGNED DRUGS ENTER HUMAN TRIALS

Isomorphic Labs president Max Jaderberg announced the development at WIRED Health in London, describing the startup's pipeline as "broad and exciting." The company represents a significant step in applying machine learning to drug discovery. AI systems can analyze molecular structures and predict how compounds will behave, potentially accelerating the traditional development process that typically takes years. Human trials mark a critical milestone for AI-designed therapeutics. It demonstrates that computational drug design has progressed beyond laboratory validation to clinical testing, where safety and efficacy are evaluated in patients. Isomorphic Labs was founded by former DeepMind scientists and has focused on applying deep learning to structural biology and drug discovery. The company's advancement to human trials suggests the approach is yielding viable candidates for treatment.